Researchers from GlaxoSmithKline have sequenced 202 drug target genes in more than 14,000 individuals in order to look for variants that would suggest novel targets or a way to repurpose existing drugs.
This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).
Epizyme is hoping that its new partnership with Celgene International Sarl will bolster the development and commercialization of its pipeline of personalized treatments that inhibit histone methyltransferase enzymes associated with specific genetic alterations.
NEW YORK (GenomeWeb News) – GlaxoSmithKline today said that it has reached an agreement to acquire the remaining 80 percent of proteomics firm Cellzome that it didn't already own for £61 million ($99 million).
Researchers at GlaxoSmithKline and their collaborators have demonstrated a method for suggesting alternative indications for existing drugs that uses data from genome wide association studies and a repository of drug information.
Canada's Prevention of Organ Failure Centre of Excellence in Vancouver is using C$1.5 million (US$1.5 million) in funding from Genome British Columbia and other groups to develop a molecular test intended to personalize treatment for chronic obstructive pulmonary disease.
By Adam Bonislawski
University of North Carolina researchers have developed a chemical proteomics approach to measure global kinase activity and used it to investigate drug resistance in triple-negative breast cancer.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Epistem today announced a research collaboration with GlaxoSmithKline to use its amplification technology to gain a better understanding of fibrosis.